Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.

Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.

Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.

Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.

Abstract: Provided are a novel therapeutic or prophylactic agent for graft-versus-host disease, a novel agent for inhibiting fibrocyte infiltration, and a novel agent for inhibiting a decrease in tear secretion and a decrease of goblet cells. A method of treating or preventing graft-versus-host disease comprises administering a phenylbutyric acid or a pharmacologically acceptable salt thereof to a patient in need of treatment or prevention of graft-versus-host disease. It is preferable that the graft-versus-host disease be a graft-versus-host disease that manifests after bone marrow transplantation. It is preferable that the graft-versus-host disease be ocular graft-versus-host disease.

Abstract: The purpose of the present disclosure is to provide a small optical integrator for increasing color mixing property and homogeneity. An optical integrator is provided with a light entrance surface and exit surface (002, 003), and side surfaces (004, 005, 006, 007) that connect the entrance surface and the exit surface, and is internally filled with a light guide material having a refractive index. The light guide material contains scattering particles for scattering light that have a refractive index different from the refractive index of the light guide material. The light that has entered via the entrance surface propagates from the entrance surface side toward the exit surface while being scattered by the scattering particles in the light guide material, wherein part of the scattered light is guided to the exit surface by propagating while being confined, by internal reflection on the side surfaces, in the light detector.

Abstract: An optical mixer efficiently homogenizes light flux emitted from a plurality of light sources emitting light having different wavelengths to provide a multi-wavelength homogeneous light source. The optical mixer has a columnar shape made of a transparent material, a length of the side surfaces is larger than an outermost diameter of a top surface or a bottom surface of the columnar shape, and a large number of scattering particles scattering light contained inside the optical mixer. The side surface of the optical mixer reflects light, and the top surface and the bottom surface thereof transmit light. Thereby, a function of mixing light incident from the top or bottom surface by the reflecting function of the side surface and the scattering function of the scattering particles is provided.

Abstract: The purpose of the present invention is to produce a chimeric antigen receptor (CAR) specific to glypican-1 (GPC-1) and to treat squamous cell carcinoma with genetically modified cells capable of expressing the CAR. The present invention provides: a chimeric antigen receptor for use in the treatment and/or prevention of squamous cell carcinoma, said chimeric antigen receptor comprising an extracellular domain capable of binding to GPC-1, a transmembrane domain and one or multiple intracellular domains, wherein at least one of the intracellular domains is an intracellular domain containing a primary cytosolic signaling sequence or an intracellular domain containing both a primary cytosolic signaling sequence and a secondary cytosolic signaling sequence; a genetically modified cell capable of expressing the chimeric antigen receptor; and a cell preparation containing the cell.

Abstract: To provide an illumination device having high efficiency, an illumination method, a video projection apparatus using the same. In order to achieve the object, there is provided an illumination device configured to include a light source and a light condensing body which condenses light from the light source to be emitted, and the light condensing body includes an incidence surface of a light source side, an emission surface emitting light, and a side surface which is present between the incidence surface and the emission surface, the side surface is a curved surface of which a distance from a light axis in a direction orthogonal to the light emitting surface of the light source at the center of the light source becomes large from the incidence surface toward the emission surface and has a plurality of curved-surface-shapes of which shapes of the curved surfaces are different from each other.

Abstract: To provide a feed that does not pollute rearing water, improves the immunity activity of leptocephalus larvae, is capable of directly feeding eel leptocephalus, and is capable of effectively inducing the growth of said larvae into glass eels. This micro-encapsulated aquaculture feed includes: an oil phase 11 having an oil-soluble nutrient component; a water phase 13 which is present inside the oil phase 11, and which includes a water-soluble nutrient component; and a film 15 which includes the oil phase 11 and the water phase 13. The water-soluble nutrient component includes at least one hydrolysate from among hydrolysates of amino acids, oligopeptides, and proteins.

Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.

Abstract: The purpose of the present disclosure is to provide a small optical integrator for increasing color mixing property and homogeneity. An optical integrator is provided with a light entrance surface and exit surface (002, 003), and side surfaces (004, 005, 006, 007) that connect the entrance surface and the exit surface, and is internally filled with a light guide material having a refractive index. The light guide material contains scattering particles for scattering light that have a refractive index different from the refractive index of the light guide material. The light that has entered via the entrance surface propagates from the entrance surface side toward the exit surface while being scattered by the scattering particles in the light guide material, wherein part of the scattered light is guided to the exit surface by propagating while being confined, by internal reflection on the side surfaces, in the light detector.

Abstract: [Problem] To provide a photosensitive resin composition for forming a member having a curved shape, which is soluble in an alkaline aqueous solution, and with which a pattern can be formed comparatively freely, wherein a lens member formed by using the said composition is excellent in heat resistance, formability of a curved shape, and transparency. [Solution] The said photosensitive resin composition for forming a member having a curved shape comprises (A) a polymer, (B) a polymerizable compound having a group which thermally reacts with the said polymer, and (C) a polymerization initiator.

Abstract: The invention features methods for inhibiting enhancement of expression of a FoxP3 gene in a cell, methods for inhibiting induction of differentiation of a cell into a regulatory T cell, methods for reducing immunosuppression, methods for stimulating tumor immunity, and methods for treating a patient with a tumor. The methods of the invention involve suppressing function of an FSTL1 protein in the cell. In the methods of the invention, function of an FSTL1 protein in the cell may be suppressed using an anti-FSTL1 antibody.

Abstract: The present invention is directed to provide diagnostic markers for melanoma, novel pharmaceutical compositions, and novel immunosuppressors. The histatin-1 mRNA and the histatin-1 protein can be used as the diagnostic markers for melanoma. In addition an inhibitor of the function that inhibits the function of the histatin-1 protein may be used as a pharmaceutical composition. Furthermore, a dendritic cell differentiated from a monocyte by the action of the histatin-1 protein or the histatin-1 protein may be used as an immunosuppressor.

Abstract: The present invention is directed to provide a cancer vaccine used for preventing and treating cancers. Provided are a peptide consisting of a sequence of SEQ ID No. 1 (KMHIRSHTL) or SEQ ID No. 2 (RTFSRMSLL) and capable of efficiently inducing cancer immunity, an antigen-presenting cell presenting this peptide on its cell surface, a T cell induced by this antigen-presenting cell as well as a cancer vaccine containing these peptides, an expression vector capable of expressing either of these peptides, the antigen-presenting cell presenting either of these peptides or the T cell induced by the antigen-presenting cell, and a method of treating and preventing cancers using the cancer vaccine.

Abstract: An object of the present invention is to provide methods for diagnosing and/or treating tumors using HERV-H env gene or HERV-H env Env protein. Specifically, tumors are diagnosed by detecting expression of HERV-H env gene; and agents for detecting the expression are used as diagnosing agents. Further, tumors are treated by inhibiting function of HERV-H env gene; and agents for inhibiting the function are used as antitumor agents. Furthermore, tumors are treated by administering a peptide having a certain sequence of HERV-H Env protein and the like; and the peptide is used as a cancer vaccine.

Abstract: The present invention provides an isolated or purified immunogenic peptide comprising 8-15 contiguous amino acids of gp100 (SEQ ID NO: 121) and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use. The invention further provides immunogenic peptides derived from gp100 which have been modified to enhance their immunogenicity and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use.

Abstract: The present invention provides an isolated or purified immunogenic peptide comprising 8-15 contiguous amino acids of gp100 (SEQ ID NO: 121) and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use. The invention further provides immunogenic peptides derived from gp100 which have been modified to enhance their immunogenicity and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use.

Abstract: The present invention provides an isolated or purified immunogenic peptide comprising 8-15 contiguous amino acids of gp100 (SEQ ID NO: 121) and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use. The invention further provides immunogenic peptides derived from gp100 which have been modified to enhance their immunogenicity and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use.